- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07938086
Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk Test
Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure: Exercise Substudy (Six-Minute Walk Test) in Ambulatory Patients
This study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient, second by second, according to oxygen saturation (SpO2), heart rate and respiratory rate measured by a pulse oximeter.
Adults with chronic respiratory disease who need oxygen during exertion perform two six-minute walk tests on the same day, 30 minutes apart: one with oxygen adjusted automatically by EMILY.AI and one with a fixed oxygen flow delivered through the same device. The order is randomized and participants do not know which test uses automatic titration.
The study compares the time spent within the target saturation range, desaturation, oxygen use, walking distance, breathlessness and participant preference between the two tests. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Background Patients with chronic respiratory disease often desaturate during exertion, and fixed-flow oxygen cannot follow the rapid changes in oxygen demand during walking and recovery. EMILY.AI combines a medical-grade oxygen valve with an edge-computing fuzzy-logic algorithm that sets the oxygen flow every second, with continuous logging of physiological signals and delivered flow.
Design Pilot, pragmatic, single-blind, randomized crossover study at Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain). Each participant performs two supervised six-minute walk tests (6MWT) according to the American Thoracic Society guideline, separated by 30 minutes of rest: one with automatic titration by EMILY.AI and one with a fixed flow set by the physician, delivered through the same device so that the participant cannot tell them apart. The order of the two tests is randomized. Each test includes 6 minutes of walking and 2 minutes of standardized recovery.
Safety The medical team knows the device configuration and supervises the valve throughout each test.
Measurements SpO2, heart rate and respiratory rate are recorded with medical-grade pulse oximeters (Nonin, Masimo or Nihon Kohden models), together with distance walked, Borg dyspnoea score, oxygen delivered and participant-reported comfort, breathlessness and preference.
The protocol FJD-EMILY-23-02 also includes a substudy in the Respiratory Intermediate Care Unit and a substudy in a conventional hospital ward, registered separately.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Alba Naya Prieto, MD
- Telefonnummer: +34 915 50 48 00
- E-Mail: alba.naya@fjd.es
Studieren Sie die Kontaktsicherung
- Name: Sarah Beatrice Heili Frades, MD, PhD
- Telefonnummer: +34 915 50 48 00
- E-Mail: SHeili@fjd.es
Studienorte
-
-
-
Madrid, Spanien, 28040
- Rekrutierung
- Hospital Universitario Fundación Jiménez Díaz
-
Kontakt:
- Sarah Beatrice Heili Frades Zimmermann MD, PhD
- Telefonnummer: +34 915 50 48 00
- E-Mail: SHeili@fjd.es
-
Kontakt:
- Alba Naya Prieto, MD
- Telefonnummer: +34 915 50 48 00
- E-Mail: alba.naya@fjd.es
-
Hauptermittler:
- Sarah Beatrice Heili Frades Zimmermann, MD, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Aged 40 to 90 years with a chronic respiratory disease.
- Indication for exertional oxygen therapy, defined as SpO2 below 88% during a six-minute walk test and/or resting respiratory failure (PaO2 below 60 mmHg).
- Able to understand the study and sign informed consent.
Exclusion Criteria:
- Decompensated acute or chronic disease with severe organ involvement, such as cardiovascular disease.
- Musculoskeletal or neurological disease preventing stable and safe walking.
- Comorbidities or treatments that, by intensity or dose, limit performance of the tests or interpretation of the results (such as alcohol use, beta-blockers, or other neurological or psychiatric drugs).
- Walking limitation preventing the six-minute walk test, or cardiovascular or connective tissue disease limiting accurate transcutaneous pulse oximetry.
- Pregnancy or breastfeeding (women of childbearing potential require a negative pregnancy test at screening).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: EMILY.AI first, then fixed flow
First 6MWT with automatic titration by EMILY.AI; after 30 minutes of rest, second 6MWT with fixed-flow oxygen through the same device. |
Investigational smart oxygen valve with an embedded fuzzy-logic algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery. Other names: EMILY.AI Smart Valve Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration. |
|
Experimental: Fixed flow first, then EMILY.AI
First 6MWT with fixed-flow oxygen through the device; after 30 minutes of rest, second 6MWT with automatic titration by EMILY.AI. |
Investigational smart oxygen valve with an embedded fuzzy-logic algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery. Other names: EMILY.AI Smart Valve Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of time with SpO2 within the target range
Zeitfenster: Day 1
|
Percentage of test time (6 minutes of walking plus 2 minutes of recovery) with SpO2, measured by pulse oximetry, within the predefined target range (88-92%), without delivering oxygen while SpO2 is above the range. Compared between the test with automatic titration by EMILY.AI and the test with fixed flow. |
Day 1
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of test time with SpO2 below 88%
Zeitfenster: Day 1
|
Percentage of test time (walking and recovery) with SpO2 below 88%, compared between conditions. |
Day 1
|
|
Number of desaturation episodes with SpO2 below 88%
Zeitfenster: Day 1
|
Number of episodes per test in which SpO2 falls below 88%, compared between conditions. |
Day 1
|
|
Time to start of oxygen flow correction
Zeitfenster: Day 1
|
Time in seconds from SpO2 leaving the target range (88-96%) to the start of an oxygen flow change, compared between conditions. |
Day 1
|
|
Time to return of SpO2 to the target range
Zeitfenster: Day 1
|
Time in seconds from SpO2 leaving the target range (88-96%) to its return to the range, compared between conditions. |
Day 1
|
|
Percentage of test time with oxygen delivered while SpO2 is above 92%
Zeitfenster: Day 1
|
Percentage of test time (walking and recovery) during which oxygen is delivered while SpO2 is above 92%, compared between conditions. |
Day 1
|
|
Number of episodes with oxygen delivered while SpO2 is above 92%
Zeitfenster: Day 1
|
Number of episodes per test in which oxygen is delivered while SpO2 is above 92%, compared between conditions. |
Day 1
|
|
Total oxygen delivered
Zeitfenster: Day 1
|
Total volume of oxygen delivered (litres) during each test including recovery, compared between conditions. |
Day 1
|
|
Mean oxygen flow
Zeitfenster: Day 1
|
Mean oxygen flow (litres per minute) delivered during each test including recovery, compared between conditions. |
Day 1
|
|
Six-minute walk distance
Zeitfenster: Day 1
|
Distance walked (metres), compared between conditions. |
Day 1
|
|
Change in dyspnoea measured with the modified Borg Dyspnoea Scale
Zeitfenster: Day 1: before and immediately after each six-minute walk test
|
Change from the start to the end of each test in dyspnoea measured with the modified Borg Dyspnoea Scale, which ranges from 0 (no breathlessness at all) to 10 (maximal breathlessness). Higher scores mean a worse outcome. Compared between conditions. |
Day 1: before and immediately after each six-minute walk test
|
|
Maximum heart rate
Zeitfenster: Day 1
|
Maximum heart rate (beats per minute) during each test, compared between conditions. |
Day 1
|
|
Maximum respiratory rate
Zeitfenster: Day 1
|
Maximum respiratory rate (breaths per minute) during each test, compared between conditions. |
Day 1
|
|
Perceived difference in exercise capacity between the two tests
Zeitfenster: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Did you notice differences in your exercise capacity in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
|
Perceived difference in breathlessness between the two tests
Zeitfenster: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Did you notice differences in shortness of breath in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
|
Perceived difference in comfort of oxygen delivery between the two tests
Zeitfenster: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Did you notice differences in the comfort of oxygen delivery in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
|
Preference between the two oxygen delivery systems
Zeitfenster: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Do you prefer either of the two oxygen systems used in the tests?", and, if so, which one. Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
|
Preference for continuous automatic flow regulation at home
Zeitfenster: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to regulate the oxygen flow continuously?". Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
|
Preference for telemonitored home oxygen
Zeitfenster: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to be telemonitored by the medical team?". Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Sarah Beatrice Heili Frades, MD, PhD, MD, PhD, Hospital Universitario Fundación Jiménez Díaz
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Pathologische Prozesse
- Chronische Erkrankung
- Krankheitsattribute
- Erkrankungen der Atemwege
- Lungenkrankheit
- Lungenerkrankungen, obstruktive
- Hypertonie
- Pathologische Zustände, Anzeichen und Symptome
- Lungenerkrankung, chronisch obstruktiv
- Lungenerkrankungen, Interstitial
- Bluthochdruck, Lungen
Andere Studien-ID-Nummern
- FJD-EMILY-23-02-TM6M
- FJD-EMILY-23-02 (Andere Kennung: Aether Tech SL)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .